Juvena Therapeutics Secures $41 Million To Accelerate The Discovery And Development Of Biologics For Chronic And Age-Related Diseases

Nov 08, 2022•about 3 years ago

Amount Raised

$41 Million

Redwood CityBiotechnology

Description

Juvena Therapeutics, Inc. (“Juvena”), a biotechnology company scaling a computational platform to map the therapeutic potential of secreted proteins, announced today that it has raised $41 million in an oversubscribed Series A, bringing its total funding to $50 million. The new funding will power the expansion of Juvena’s drug discovery platform and advance the company’s biologics pipeline targeting chronic and age-related diseases.

Company Information

Company

Juvena Therapeutics

Location

Redwood City, California, United States

About

Juvena Therapeutics is a biotech company accelerating the development of therapeutics by unlocking the therapeutic potential of secreted proteins. Secreted proteins are a class of biologics with proven therapeutic potential that has been under-leveraged due to the complexity of identifying and screening such proteins. The company is developing a patent-pending computational drug discovery and development platform that is delivering novel biologics to address major unmet medical needs in chronic and age-related diseases by mining regenerative proteins secreted by stem cells. Juvena has generated hits and new drug targets across several therapeutic areas.

Related People

2 contacts

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Juvena Therapeutics Secures $41 Million To Accelerate The Discovery And Development Of Biologics For Chronic And Age-Related Diseases

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Related People

Funding Insights

Company Information